Request Consultation
These prescribed medications are subcutaneous injections specifically designed for patients managing genetically high cholesterol or living with existing heart disease. By effectively lowering low-density lipoprotein, they provide a crucial defense mechanism against future cardiovascular events for vulnerable individuals requiring intensive lipid management and ongoing medical care.
Diverse catalysts are fueling the overall expansion & development injection for high cholesterol, such as:
- A prominent driver is a massive rise in the prevalence of high cholesterol & related heart illness, which are propelled by sedentary lifestyles, genetic factors, & geriatric populations, and this raises demand for advanced lipid-lowering therapies.
- In case of statin intolerance, injectable therapies provide potent options to lower LDL by 50% or more.
- Alongside, immersive groundbreakings in drug delivery, including Inclisiran, give a long-acting advantage, decline pill fatigue & hugely enhance patient adherence as compared to daily oral medications.
Key Brands are Fostering Innovations in Injection for the High Cholesterol Sector
| Category | Brand Name (Manufacturer) | MOA |
| siRNA (Small Interfering RNA) | Leqvio (Novartis) | This primarily uses RNA interference to target & silence the PCSK9 gene at the cellular level. Also, preventing the liver from ever producing the PCSK9 protein allows it to absorb more bad cholesterol (LDL) from the blood. |
| Monoclonal Antibodies (PCSK9 Inhibitors) | Repatha (Amgen) | Specifically, a fully human monoclonal antibody directly binds to circulating PCSK9 proteins in the blood & blocks them from degrading LDL receptors. |
| Praluent (Sanofi/ Regeneron) | This mainly acts by neutralizing circulating PCSK9 proteins, with the prevention of the degradation of LDL receptors, and boosting the liver's ability to pull LDL cholesterol out of the circulation. |
Net Sales of the Leaders of the Injection for High Cholesterol Industry in 2025
- Firstly, the worldwide sales of Leqvio were $1.198 billion in 2025, which shows a nearly 59% rise compared to 2024.
- Whereas the Repatha brand reached $3.016 billion in global sales, demonstrating a 36% increase year-over-year.
- Moreover, Praluent generated €526 million in global sales in 2025, which is more than 8.9% than 2024.
Future Outlook: Innovation Driving the Cholesterol Injection Market
The injection for high cholesterol market is advancing rapidly through innovative biologics, RNA-based therapies, and long-acting treatment approaches. Leading brands, including Leqvio, Repatha, and Praluent, continue strengthening their market positions through superior LDL-lowering efficacy, improved adherence, and expanding clinical adoption. Rising cardiovascular disease prevalence, increasing cases of statin intolerance, and ongoing pharmaceutical innovation are expected to accelerate demand, positioning injectable cholesterol therapies as a transformative segment in modern cardiovascular disease management globally.
About the Experts
Aditi Shivarkar
Aditi leads as Vice President at Towards Healthcare and brings over 15 years of experience in healthcare research, innovation, and strategy. She works closely with data from across the healthcare sector and turns it into clear direction that companies can actually use. Her work covers pharmaceuticals, medical devices, and digital health. She helps businesses understand where the market is going and how to respond with confidence. Aditi focuses on practical thinking, strong decision-making, and delivering real results that make a difference.
Aman Singh
Aman Singh brings over 13 years of experience in healthcare research and consulting. He studies global healthcare trends and keeps a close eye on areas like biotech, AI in healthcare, and new treatment approaches. At Towards Healthcare, he leads the research team and makes sure the work stays accurate, useful, and easy to understand. Aman breaks down complex changes in the industry and helps businesses make smart, informed decisions.
Piyush Pawar
Piyush Pawar works as Senior Manager for Sales and Business Growth at Towards Healthcare, with more than 10 years of experience in the healthcare space. He works directly with clients and helps them find the right research for their needs. He makes sure clients understand the insights and know how to use them in their business. Piyush builds strong relationships and focuses on helping companies grow by turning research into clear, practical action.
